Literature DB >> 21685193

N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.

Maria Prastaro1, Stefania Paolillo, Gianluigi Savarese, Santo Dellegrottaglie, Oriana Scala, Donatella Ruggiero, Paola Gargiulo, Caterina Marciano, Antonio Parente, Milena Cecere, Francesca Musella, Donato Chianese, Francesco Scopacasa, Pasquale Perrone-Filardi.   

Abstract

AIMS: Amino-terminal portion of pro-B-type natriuretic peptide (NT-pro-BNP) is a valuable diagnostic and prognostic marker in congestive heart failure (CHF). In CHF patients, elevation of natriuretic peptide levels correlate with decreased left ventricular (LV) ejection fraction (EF) and increased left atrial (LA) volumes, but a correlation with LA function that is a determinant of haemodynamic and clinical status in CHF with independent prognostic value has never been investigated. Aim of this study was to evaluate the relationship between cardiac neurohormonal activation and LA function in patients with CHF due to dilated cardiomyopathy. METHODS AND
RESULTS: One hundred and one patients (86% males; mean age, 64 ± 11 years) with dilated ischaemic or non-ischaemic cardiomyopathy, LV EF ≤45% (mean LV EF, 33 ± 8%), and New York Heart Association class II-IV underwent transthoracic echocardiography to evaluate LA fractional active and total emptying from M- and B-Mode images, and, on the same day, venous blood sample collection to dose NT-pro-BNP. By univariate analyses, NT-pro-BNP significantly correlated to age, LA dimensions, LA function indexes, EF, and functional class. At multivariate analysis, LV EF and M- or B-Mode indexes of LA function were the only independent predictors of NT-pro-BNP values. A NT-pro-BNP cut-off of 1480 pg/mL identified LA dysfunction with 89% specificity and 54% sensitivity.
CONCLUSION: In CHF patients with severely impaired systolic function, NT-pro-BNP levels reflect LA and LV dysfunction. These data should prompt studies to investigate the relationship between changes of LA function and NT-pro-BNP levels and their clinical value as prognostic and therapeutic targets in CHF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685193     DOI: 10.1093/ejechocard/jer070

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  5 in total

1.  Association between pericoronary adipose tissue attenuation and outcome after second-generation cryoballoon ablation for atrial fibrillation.

Authors:  Kai Nogami; Tomoyo Sugiyama; Yoshihisa Kanaji; Masahiro Hoshino; Satoshi Hara; Masao Yamaguchi; Masahiro Hada; Yohei Sumino; Toru Misawa; Hidenori Hirano; Hiroki Ueno; Naoyuki Miwa; Kazuya Yamao; Shigeki Kusa; Hitoshi Hachiya; Tsunekazu Kakuta
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

2.  NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis.

Authors:  Roman Maslennikov; Anastasia Driga; Konstantin Ivashkin; Vladimir Ivashkin
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

3.  Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.

Authors:  John Bisognano; John E Schneider; Shawn Davies; Robert L Ohsfeldt; Elizabeth Galle; Ivana Stojanovic; Thomas F Deering; JoAnn Lindenfeld; Michael R Zile
Journal:  BMC Cardiovasc Disord       Date:  2021-03-26       Impact factor: 2.298

4.  Left atrial reservoir strain as a predictor of cardiac outcome in patients with heart failure: the HaFaC cohort study.

Authors:  Sjoerd Bouwmeester; Jonna A van der Stam; Saskia L M van Loon; Natal A W van Riel; Arjen-Kars Boer; Lukas R Dekker; Volkher Scharnhorst; Patrick Houthuizen
Journal:  BMC Cardiovasc Disord       Date:  2022-03-14       Impact factor: 2.298

5.  Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.

Authors:  Gianluigi Savarese; Bruno Trimarco; Santo Dellegrottaglie; Maria Prastaro; Francesco Gambardella; Giuseppe Rengo; Dario Leosco; Pasquale Perrone-Filardi
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.